Sanofi and Teva’s Duvakitug Achieves Key Milestones in Phase 2b Study for Ulcerative Colitis and Crohn’s Disease

Sanofi and Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd., announced that the RELIEVE UCCD phase 2b study met its primary endp...

December 18, 2024 | Wednesday | News
EMA Committee Issues Positive Opinion for Long-Acting HIV Treatment Vocabria + Rekambys for Adolescents

GSK plc (LSE/NYSE: GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, ...

December 17, 2024 | Tuesday | News
Novo Nordisk Commits 8.5 Billion DKK to Transformative Production Facility in Odense, Strengthening Denmark and Europe’s Biopharma Landscape

Novo Nordisk announced plans to invest 8.5 billion Danish kroner to establish a completely new production facility in Odense, Denmark. The investment mar...

December 16, 2024 | Monday | News
Eli Lilly's Omvoh® (Mirikizumab) Receives Positive CHMP Opinion for Crohn’s Disease in the EU

Eli Lilly and Company (NYSE: LLY) announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human ...

December 16, 2024 | Monday | News
Merck’s WELIREG® Receives Positive CHMP Opinion for VHL Disease-Associated Tumors and Advanced RCC in the EU

Positive CHMP opinion brings us closer to offering WELIREG, a first-in-class HIF-2α inhibitor, to certain patients in the European Union, in order to...

December 16, 2024 | Monday | News
Roche Announces European Approval of Vabysmo® Prefilled Syringe for Treatment of Major Retinal Diseases

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the European Medicines Agency has approved Vabysmo® (faricimab) 6.0 mg single-dose prefilled syringe ...

December 16, 2024 | Monday | News
AstraZeneca and Merck Announce Six-Year Data from OlympiA Trial, Showing LYNPARZA Significantly Improves Survival in BRCA-Mutated Early Breast Cancer

 AstraZeneca and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced long-term results from the OlympiA Phase 3 trial w...

December 13, 2024 | Friday | News
Sanofi Advances First Non-mRNA Flu-COVID Combination Vaccines with FDA Fast Track Designation

First non-mRNA combination vaccine candidates that include two already licensed vaccines to prevent influenza and COVID-19 infections Two phase 1/2 cl...

December 11, 2024 | Wednesday | News
Pilatus Biosciences' PLT012 Receives Orphan Drug Designation for Liver and Intrahepatic Bile Duct Cancer

Pilatus Biosciences Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its leading molecule, PLT0...

December 11, 2024 | Wednesday | News
Nona Biosciences Partners with Kodiak Sciences to Advance Multi-Target Antibodies for Ophthalmic Diseases

Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to ITM), ranging from target validation and antibody disc...

December 10, 2024 | Tuesday | News
AstraZeneca’s Imfinzi Gains FDA Approval for Limited-Stage Small Cell Lung Cancer, Offering New Hope for Patients

AstraZeneca’s Imfinzi (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cance...

December 09, 2024 | Monday | News
Nxera Pharma Launches Phase 3 Trial of QUVIVIQ™ (Daridorexant) in South Korea to Address Insomnia Epidemic

Daridorexant is a dual orexin receptor antagonist being developed by Nxera for the treatment of adult patients with insomnia QUVIVIQ™ (daridorex...

December 05, 2024 | Thursday | News
Amarna Therapeutics Forms Strategic Partnership with NorthX Biologics to Advance Gene Therapy Development

Amarna Therapeutics, (“Amarna” or “the Company”), a privately held biotechnology company specializing in transformative gene therap...

December 04, 2024 | Wednesday | News
Smart Immune and CELLforCURE Partner to Scale SMART101 Production for Advanced Cell Therapy Trials

Smart Immune, a clinical-stage biotechnology company, and CELLforCURE by SEQENS, a Contract  Development and Manufacturing Organization (CDMO) for Adv...

December 03, 2024 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close